Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CognatiQ is a patented, clinically validated dietary supplement ingredient derived from the whole fruit of the Coffea arabica plant. It is standardized to contain at least 40% chlorogenic acids and minimal caffeine content. The key mechanism of action is its ability to significantly increase levels of brain-derived neurotrophic factor (BDNF), a neuroprotein essential for neurogenesis, synaptic plasticity, and overall cognitive function. Clinical studies have demonstrated that both acute (single dose) and chronic supplementation with CognatiQ can rapidly improve working memory, focus, accuracy, concentration, mental clarity, and information retention in healthy adults. These effects are attributed to its unique polyphenol profile—especially chlorogenic acid—which provides antioxidant and anti-inflammatory benefits while supporting neuronal health. Developed by FutureCeuticals using a sustainable process that utilizes the entire coffee fruit (skin, pulp, bean), CognatiQ is used as an ingredient in various cognitive health supplements and functional foods[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CognatiQ.